Brooke M. VandenBrink

Prediction of CYP2D6 Drug Interactions from In Vitro Data: Evidence for Substrate-Dependent Inhibition

Brooke M. VandenBrink, R. Foti, Dan A. Rock et al. · Drug Metabolism and Disposition · 2011 · 77 citations

Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate

Brooke M. VandenBrink, R. Foti, Dan A. Rock et al. · Drug Metabolism and Disposition · 2011 · 71 citations

Sequential Metabolism of Secondary Alkyl Amines to Metabolic-Intermediate Complexes: Opposing Roles for the Secondary Hydroxylamine and Primary Amine Metabolites of Desipramine, (S)-Fluoxetine, and N-Desmethyldiltiazem

Kelsey L. Hanson, Brooke M. VandenBrink, K. Nagendra Babu et al. · Drug Metabolism and Disposition · 2010 · 45 citations · Full text

In Vitro Hepatotoxicity and Cytochrome P450 Induction and Inhibition Characteristics of Carnosic Acid, a Dietary Supplement with Antiadipogenic Properties

Leslie J. Dickmann, Brooke M. VandenBrink, Yvonne S. Lin · Drug Metabolism and Disposition · 2012 · 44 citations · Full text

Sequential Metabolism of AMG 487, a Novel CXCR3 Antagonist, Results in Formation of Quinone Reactive Metabolites That Covalently Modify CYP3A4 Cys239 and Cause Time-Dependent Inhibition of the Enzyme

Kirk R. Henne, Thuy Tran, Brooke M. VandenBrink et al. · Drug Metabolism and Disposition · 2012 · 41 citations · Full text